Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.70 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.62 |
| ▸ | THRA | P10827 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802422 | 0.87 | PTGDR2 (0.76) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL4209387 | 0.86 | PTGDR2 (0.74) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL4211522 | 0.85 | PTGDR2 (0.72) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL4200412 | 0.84 | PTGDR2 (0.69) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL1939826 | 0.82 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL4270126 | 0.82 | THRA (0.71) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL13802404 | 0.81 | PTGDR2 (1.00) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL13802427 | 0.81 | THRA (0.65) | PTGDR2PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL29941473 | 0.80 | PLA2G2A (0.75) | PTGDR2PLA2G2AGFER | |
| SCHEMBL20769712 | 0.80 | PTGDR2 (0.69) | PTGDR2PLA2G2ATHRATHRBPLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGDR2 2287/4885PLA2G2A 409/4885THRA 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.